2026 year-to-date · Quality account performance
47
Events Attended YTD
+12% vs 2025
312
Total Patient Contacts
+8% vs 2025
67%
Cardiac Arrest ROSC Rate
4/6 ROSC · National 30%
1.8
Incident Rate / 1000 Attendees
−0.3 vs 2025
1m 42s
Avg Response Time (on-event)
−18s vs 2025
94%
CQC Compliance Score
Self-assessed May 2026
1
↑ 1 this month
6
Average 14d to close
7
0 critical
6
2 complete YTD
6
1 action open
3
3 complaints
88%
Mean compliance across 4 audits
| Drug | Admins |
|---|---|
| Entonox (inhaled) | 67 |
| Salbutamol (nebulised) | 22 |
| Adrenaline 1mg IV | 6 |
| Amiodarone 300mg IV | 4 |
| Oral glucose / glucagon IM | 18 |
| Midazolam IM (PGD) | 9 |
| Naloxone IN/IV | 5 |
0 Duty of Candour conversation outstanding
Open →1 clinical audit re-audit due
Audit programme →1 complaint with PHSO — Trust Board oversight
Open →DSPT Standards Met 2025/26 — re-submit 30 Jun 2026
Quality Account 2025/26 published 30 Apr 2026